ACCEPT: A phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL)

被引：1
|
作者：
Johnson, Peter W. M. [1 ]
Caddy, Joshua [2 ]
Cumin, Tom [1 ]
Merton, Bridgen [1 ]
Maishman, Tom [2 ]
Galanopoulou, Angelic [2 ]
Griffiths, Gareth [2 ]
Davies, Andrew [1 ]
机构：
[1] CRUK Ctr, Southampton, Hants, England
[2] Southampton Clin Trials Unit, Southampton, Hants, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT162
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Prognostic significance of primary extranodal diffuse large B-cell lymphoma (DLBCL) in patients treated with R-CHOP
    Hui, D.
    Proctor, B.
    Donaldson, J.
    Shenkier, T.
    Hoskins, P.
    Klasa, R.
    Savage, K.
    Gascoyne, R.
    Connors, J. M.
    Sehn, L. L.
    ANNALS OF ONCOLOGY, 2008, 19 : 186 - 187
  • [32] Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study
    Kate Manos
    Geoffrey Chong
    Colm Keane
    Sze-Ting Lee
    Charmaine Smith
    Leonid Churilov
    Joseph McKendrick
    William Renwick
    Piers Blombery
    Melinda Burgess
    Niles Elizabeth Nelson
    Tineke Fancourt
    Joanne Hawking
    Wendi Lin
    Andrew M. Scott
    Allison Barraclough
    Joel Wight
    Andrew Grigg
    Chun Yew Fong
    Eliza A. Hawkes
    Leukemia, 2023, 37 : 1092 - 1102
  • [33] Promising results of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma
    Micallef, I. N.
    Maurer, M.
    Nikcevich, D.
    Cannon, M.
    Moore, D.
    Kurtin, P.
    Schaefer, E.
    Witzig, T.
    ANNALS OF ONCOLOGY, 2008, 19 : 161 - 161
  • [34] Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study
    Manos, Kate
    Chong, Geoffrey
    Keane, Colm
    Lee, Sze-Ting
    Smith, Charmaine
    Churilov, Leonid
    McKendrick, Joseph
    Renwick, William
    Blombery, Piers
    Burgess, Melinda
    Nelson, Niles Elizabeth
    Fancourt, Tineke
    Hawking, Joanne
    Lin, Wendi
    Scott, Andrew M.
    Barraclough, Allison
    Wight, Joel
    Grigg, Andrew
    Fong, Chun Yew
    Hawkes, Eliza A.
    LEUKEMIA, 2023, 37 (05) : 1092 - 1102
  • [35] Prognostic significance of primary extranodal diffuse large B-cell lymphoma (DLBCL) in patients treated with R-CHOP
    Proctor, B. R.
    Hui, D.
    Donaldson, J.
    Savage, K. J.
    Shenkier, T. N.
    Hoskins, P. J.
    Klasa, R.
    Randy, G.
    Joseph, C.
    Sehn, L. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study
    Tilly, Herve
    Morschhauser, Franck
    Bartlett, Nancy L.
    Sharman, Jeff
    Haioun, Corinne
    Kolibaba, Kathryn S.
    Chen, Andy
    Lamy, Thierry
    Jones, Surai
    Penuel, Elicia
    Lee, Calvin
    Salles, Gilles A.
    BLOOD, 2016, 128 (22)
  • [37] Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
    Suzuki, Tomotaka
    Maruyama, Dai
    Miyagi-Maeshima, Akiko
    Nomoto, Junko
    Tajima, Kinuko
    Ito, Yuta
    Hatta, Shunsuke
    Yuda, Sayako
    Makita, Shinichi
    Fukuhara, Suguru
    Munakata, Wataru
    Suzuki, Tatsuya
    Taniguchi, Hirokazu
    Izutsu, Koji
    Kobayashi, Yukio
    Tobinai, Kensei
    CANCER MEDICINE, 2021, 10 (15): : 5101 - 5109
  • [38] Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
    Mounier, N
    Briere, J
    Gisselbrecht, C
    Emile, JF
    Lederlin, P
    Sebban, C
    Berger, F
    Bosly, A
    Morel, P
    Tilly, H
    Bouabdallah, R
    Reyes, F
    Gaulard, P
    Coiffier, B
    BLOOD, 2003, 101 (11) : 4279 - 4284
  • [39] Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubucin and Rituximab (da-EPOCH-R) Vs Rituxan, Cyclophosphamide, Doxorubucin, Vincristine and Prednisone (R-CHOP) As First Line Treatment for Diffuse Large B-Cell Lymphoma (DLBCL)
    Padhi, Parikshit
    Chilkulwar, Abhishek
    Khan, Cyrus
    Patel, Monank
    Lister, John
    Tang, Xiaoqin
    BLOOD, 2016, 128 (22)
  • [40] Phase II/III Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab (R-CHOP) Versus Biweekly CHOP with Rituximab (R-Bi-CHOP) In Untreated Advanced-Stage Indolent B-Cell Lymphoma: Japan Clinical Oncology Group (JCOG) 0203 Trial
    Watanabe, Takashi
    Morishima, Yasuo
    Shibata, Taro
    Maseki, Nobuo
    Kinoshita, Tomohiro
    Suzuki, Takayo
    Yamaguchi, Motoko
    Ando, Kiyoshi
    Ogura, Michinori
    Taniwaki, Masafumi
    Uike, Naokuni
    Takeuchi, Kengo
    Nawano, Shigeru
    Terauchi, Takashi
    Tsukasaki, Kunihiro
    Hotta, Tomomitsu
    Tobinai, Kensei
    BLOOD, 2010, 116 (21) : 193 - 193
12345